
Opinion|Videos|June 5, 2017
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
Author(s)Kim N. Chi, MD
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Advertisement
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Belzutifan Demonstrates Promise in Von Hippel-Lindau Disease
2
PHERFLOT Trial: Perioperative Promise in HER2+ Esophagogastric Adenocarcinoma
3
Uncovering Clinical Risk Factors for T-DXd Pneumonitis in Metastatic Breast Cancer
4
Glofitamab Plus Polatzumab Vedotin Demonstrates High Early Efficacy in LBCL
5








































